fda bpc 157 category 2 compounding list panel votes to place popular peptide BPC-157 on You may have heard buzz

You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them 3 FOR 3. An FDA advisory committee has now voted 86, with one abstention, to recommend BPC 157, KPV and TB 500 for inclusion on the 503A Bulks List. This is not FDA approval I am getting so many messages there is a lot to review and a lot unfolding quickly! I want to take my time with the information and have been studying on rotations. Hopefully will get yall an only FDA is reviewing seven peptides this week, BPC 157, MOTS c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline FDA removes BPC 157, KPV, Semax from Category 2 on April 22 but they are not legal to compound yet PeptideKnow

SKU: 65730240663 · From meijijudolehavre.com